en

PRODUCT DETAIL

Ruxience 500 mg infúzny koncentrát

Code 4425D
MA number EU/1/20/1431/002
Product Form: con inf 1x50 ml/500 mg (liek.inj.skl.)
MA Status: E - Valid centralised marketing authorisation
Type of procedure: EU
Therapeutic Class: 59 - IMMUNOPRAEPARATA
ATC:
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01F MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
L01FA CD20 (Clusters of Differentiation 20) inhibitors
L01FA01 Rituximab
Shelf life: 24
Container: glass vial
Route of admin.: Intravenous use
Prescription Status: Medicinal product subject to restricted medical prescription.
Legal basis: Article 10(4) similar biological application
MA issued: 01.04.2020
Validity: 01.04.2025
SmPC + PL: European Medicines Agency's database
Safety feature Yes
Data update: 14.12.2022
eu-flag.png sk-flag.png